Your session is about to expire
← Back to Search
Radiation + Hormone Therapy for Prostate Cancer (SChLAP/IDC Trial)
SChLAP/IDC Trial Summary
This trial is testing if adding a new hormone therapy to standard radiation therapy for prostate cancer will work better than standard therapy alone in men with a certain genetic marker and cancer cell arrangement.
SChLAP/IDC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSChLAP/IDC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SChLAP/IDC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had recent heart problems like unstable angina, heart attacks, or heart failure.My hemoglobin level is below 9.0 g/dL without transfusions.I am on medication that could react badly with darolutamide.My prostate cancer is intermediate-risk with specific PSA levels, Gleason score, or tumor size.I am planning to start a new treatment for prostate cancer.I have not taken any hormone therapy for my condition in the last year.My recent scans show no cancer spread to pelvic lymph nodes.I was diagnosed with prostate cancer in the last 6 months.My recent scans show no cancer spread to my bones.I am currently taking blood thinners for a health condition.I am able to get out of my bed or chair and move around.I have received chemotherapy for prostate cancer.My kidney function is not normal, with high creatinine or low GFR.I am a man aged 18 or older.My prostate cancer is considered to be at an intermediate risk level.
- Group 1: Group 2: Radiation Therapy + darolutamide + degarelix
- Group 2: Group 1: Radiation Therapy Only
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is it possible to enroll in this venture at present?
"As indicated by the records on clinicaltrials.gov, enrollment for this trial has been paused at present; it was initially posted on November 1st 2022 and last updated April 13th of that year. Nonetheless, there are over a thousand other trials accepting participants currently."
Is this experiment unique among similar protocols?
"The first study of Radiation Therapy was conducted in 2012 by Ferring Pharmaceuticals and involved 41 patients. Following the initial trial, it obtained N/A drug approval, allowing for 53 current studies to be held across 848 cities and 45 nations."
Has the FDA sanctioned radiation therapy for medical use?
"Our team at Power rated Radiation Therapy's safety a 2, since this is a Phase 2 trial with evidence for its safety but not yet effectiveness."
Could you please provide an overview of historical investigations related to Radiation Therapy?
"Presently, there are 53 ongoing investigations into Radiation Therapy of which 16 have reached Phase 3. Of those trials, the vast majority can be found in Los Angeles but the treatment is being trialled at a total of 2680 sites across America."
What is the current participant headcount for this medical experiment?
"This medical trial is no longer accepting participants. It was initially listed on November 1st 2022 and the most recent edit occurred April 13th 2022. If you are looking for alternative research opportunities, there are currently 1315 trials recruiting patients diagnosed with prostate cancer and 53 Radiation Therapy studies actively enrolling individuals at this time."
Share this study with friends
Copy Link
Messenger